Document Detail

Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
MedLine Citation:
PMID:  2501516     Owner:  NLM     Status:  MEDLINE    
With data from 2 large randomized British Medical Research Council studies we identified several factors influencing the recurrence of newly diagnosed superficial bladder cancer. Using multivariate methods to assess the relative importance of these factors we found the most important to be the result of cystoscopy performed 3 months after initial transurethral resection and the number of tumors (single or multiple) at presentation. With these 2 factors we divided the patient population into 3 groups with varying degrees of prognosis. Different followup procedures are proposed for each of these 3 groups.
M K Parmar; L S Freedman; T B Hargreave; D A Tolley
Related Documents :
10910226 - Urinary tract cancer screening through analysis of urinary red blood cell volume distri...
20001606 - Urinary diversion after cystectomy for bladder cancer: a population-based study in sweden.
19711266 - Palliative treatment of intractable hematuria in context of advanced bladder cancer: a ...
1305676 - New opportunities for screening and early detection of bladder cancer.
9688246 - The use of serum ca-125 as a marker for endometriosis in patients with dysmenorrhea for...
1995356 - Limited resection for stage i lung cancer.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of urology     Volume:  142     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1989-08-25     Completed Date:  1989-08-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  284-8     Citation Subset:  AIM; IM    
MRC Cancer Trials Office, Cambridge, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Intravesical
Carcinoma, Transitional Cell / drug therapy,  mortality*
Follow-Up Studies
Mitomycins / therapeutic use
Multicenter Studies as Topic
Neoplasm Recurrence, Local*
Statistics as Topic
Thiotepa / therapeutic use
Time Factors
Urinary Bladder Neoplasms / drug therapy,  mortality*
Reg. No./Substance:
0/Mitomycins; 50-07-7/Mitomycin; 52-24-4/Thiotepa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vitro processing of dengue virus structural proteins: cleavage of the pre-membrane protein.
Next Document:  The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in...